Pitcairn Co. Cuts Position in Pfizer Inc. (NYSE:PFE)

Pitcairn Co. reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 21.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,677 shares of the biopharmaceutical company’s stock after selling 5,592 shares during the period. Pitcairn Co.’s holdings in Pfizer were worth $549,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of PFE. Retirement Wealth Solutions LLC acquired a new stake in Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer in the fourth quarter valued at $28,000. Noble Wealth Management PBC acquired a new position in Pfizer during the 4th quarter worth $31,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer during the 4th quarter worth about $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on PFE shares. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reissued a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Bank of America reiterated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Finally, UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Performance

Shares of Pfizer stock opened at $22.99 on Friday. The stock has a market capitalization of $130.39 billion, a price-to-earnings ratio of 16.31, a PEG ratio of 0.64 and a beta of 0.67. The firm’s fifty day simple moving average is $25.87 and its 200-day simple moving average is $26.74. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 12 month low of $22.95 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the company earned $0.10 earnings per share. The business’s revenue was up 24.7% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.